Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System

Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System

ABSTRACT Objective: Lung cancer is an important health problem due to its high incidence and mortality. The treatment of metastatic disease improved after the molecular pathways of cancer came to be known. However, targeted therapy is unavailable to many patients treated within the Brazilian Sistem...

Full description

Bibliographic Details
Main Authors:	Pedro Aguiar Jr, Felipe Roitberg, Gilberto Lopes Jr, Auro del Giglio
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Pneumologia e Tisiologia
Series:	Jornal Brasileiro de Pneumologia
Subjects:	health policy molecular targeted therapy economics, pharmaceutical brazil
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132020000400206&lng=en&tlng=en

Similar Items

Unicistes versus pluralistes : l’homéopathie brésilienne à l’ère de la globalisation
by: Armelle Giglio-Jacquemot

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer
by: Pedro Nazareth Aguiar Jr., et al.

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

The potential of telemedicine in alleviating out-of-pocket costs for oncological patients in the Brazilian public healthcare system
by: José Favoreto-Neto, et al.
Published: (2023-10-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
by: Tasia Amelia, et al.
Published: (2022-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
by: Igor Makhlin, et al.
Published: (2019-11-01)

The Brazilian private pharmaceutical market after the first ten years of the generics law
by: Andréa Dâmaso Bertoldi, et al.
Published: (2019-12-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
by: Panupong Mahalapbutr, et al.
Published: (2024-02-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

The clinical pharmacist’s role in a high-cost medicine pharmacy: Patient-centered care
by: Lenyta Oliveira Gomes, et al.
Published: (2022-12-01)

Proposal of managerial standards for new product portfolio management in Brazilian pharmaceutical companies
by: Raquel Assis Moreira, et al.
Published: (2010-03-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
by: Kenichi Suda, et al.
Published: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
by: Xingyuan Li, et al.
Published: (2023-10-01)

Psychiatry, bio-epistemes and the making of adolescence in southern Brazil
by: Dominique Pareja Béhague

Outcomes of pharmaceutical care in Brazil: a literature review
by: Ingrid Stephanie Stein Ambiel, et al.
Published: (2013-10-01)

Addressing challenges in the implementation of precision oncology: An in-depth examination of limitations and disparities in the treatment of non-small cell lung cancer in the Brazilian public healthcare system (SUS)
by: Luma Princess Schneider, et al.
Published: (2025-12-01)

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
by: Okumura LM, et al.
Published: (2015-06-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
by: Marcin Skrzypski, et al.
Published: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
by: Daniel B Costa, et al.
Published: (2007-10-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019-11-01)

Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations
by: Pedro Nazareth Aguiar Jr., et al.

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
by: D. D. SAKAEVA
Published: (2017-06-01)

Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
by: Elena V. Poddubskaya, et al.
Published: (2018-09-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

Comparative analysis of mastectomies and breast reconstructions performed in the Brazilian Unified Health System in the last 5 years
by: Caroline Silva Costa de Almeida, et al.
Published: (2021-09-01)

Gefitinib (Iressa®) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center
by: Auro del Giglio, et al.

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

Lawsuits against the Brazilian Unified Health System regarding Bladder/Ureteral Cancer
by: Fernando Korkes, et al.
Published: (2024-01-01)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
by: Esuteru Hirokawa, et al.
Published: (2021-08-01)

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies
by: Thitinan Aiebchun, et al.
Published: (2021-04-01)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
by: Rafael Rosell, et al.
Published: (2015-06-01)

Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
by: Xiaohan Zhou, et al.
Published: (2020-01-01)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016-10-01)

Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors
by: Xiuqin Hu, et al.
Published: (2017-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
by: Cornelius Hempel, et al.
Published: (2017-01-01)

Clinicopathological Characteristics and Real-life Data of Patients Receiving Tyrosine Kinase Inhibitor in Metastatic EGFR Mutant Non-small Cell Lung Carcinoma
by: Barış EKİNCİ, et al.
Published: (2023-12-01)

Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
by: Yun Jung Choi, et al.
Published: (2013-01-01)